These ectopic receptors influence GLP-1 and GIP secretion, serotonin and dopamine secretion, blood pressure, muscle ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well to current treatments.

chronic kidney disease and a history of heart attack or a history of heart failure. Within the entire study period, the death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11 ...

Q4 2024 Earnings Call Transcript November 7, 2024 Operator: Hello and welcome to BD’s Fourth Quarter and Full Year Fiscal ...

A new study has found that SGLT-2 inhibitor drugs for type 2 diabetes may also reduce the risk of kidney stones and gout. These painful conditions are ...

KEY BUSINESS HIGHLIGHTSPhase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to ...